Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  European Neuropsychopharmacology

• Publication date

  2012-04-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/j.euroneuro.2011.10.003PMID 22137564
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Is 5-HTTLPR linked to the response of selective serotonin reuptake inhibitors in MDD?

  2011cited by this paper
• Predictive factors for responding to sertraline treatment : views from plasma catecholamine metabolites and serotonin transporter polymorphism

  2011cited by this paper
• A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders

  2011cited by this paper
• The serotonin transporter polymorphism (5‐HTTLPR): allelic variation and links with depressive symptoms

  2010influential reference
• Serotonin Transporter Gene Polymorphism Associated with Short-Term Treatment Response to Venlafaxine

  2010cited by this paper
• Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms.

  2010cited by this paper
• Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder

  2010cited by this paper
• Rare genotype combination of the serotonin transporter gene associated with treatment response in severe personality disorder

  2010influential reference
• Pharmacogenetics of antidepressive treatment

  2010cited by this paper
• Genetic polymorphisms in the treatment of depression: speculations from an augmentation study using atomoxetine.

  2010influential reference
• Norepinephrine and Serotonin Transporter Genes: Impact on Treatment Response in Depression

  2010cited by this paper
• Predictive factors for responding to sertraline treatment: views from plasma catecholamine metabolites and serotonin transporter polymorphism

  2010cited by this paper
• Antidepressant response and the serotonin transporter gene-linked polymorphic region.

  2010influential reference
• Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorder

  2009influential reference
• Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression.

  2009influential reference
• Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy

  2009influential reference
• When is Pharmacogenetic Testing for Antidepressant Response Ready for the Clinic? A Cost-effectiveness Analysis Based on Data from the STAR*D Study

  2009cited by this paper
• 5-HTTLPR modulates antidepressant efficacy in depressed women

  2009cited by this paper
• Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant response

  2009influential reference
• Interaction between genetic polymorphisms and stressful life events in first episode depression.

  2009cited by this paper
• Moderation of antidepressant response by the serotonin transporter gene

  2009influential reference
• SLC6A4 variation and citalopram response

  2009influential reference
• Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans

  2009cited by this paper
• Harm avoidance moderates the influence of serotonin transporter gene variants on treatment outcome in bipolar patients.

  2009cited by this paper
• New approaches to the pharmacological management of major depressive disorder.

  2009cited by this paper
• Rapid response to paroxetine is associated with plasma paroxetine levels at 4 but not 8 weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patients

  2009cited by this paper
• Understanding heterogeneity in meta‐analysis: the role of meta‐regression

  2009cited by this paper
• Common genetic, clinical, demographic and psychosocial predictors of response to pharmacotherapy in mood and anxiety disorders

  2009cited by this paper
• Serotonin transporter gene and response to lithium augmentation in depression

  2008cited by this paper
• Serotonin transporter polymorphism (5‐HTTLPR) association with melancholic depression: a female specific effect?

  2008cited by this paper
• No predictors of antidepressant patient response to milnacipran were obtained using the three‐factor structures of the Montgomery and Åsberg Depression Rating Scale in Japanese patients with major depressive disorders

  2008cited by this paper
• Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder.

  2008cited by this paper
• Lithium overcomes the influence of 5-HTTLPR gene polymorphism on antidepressant response to sleep deprivation.

  2008cited by this paper
• Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorder

  2008cited by this paper
• Serotonin Transporter Gene Polymorphisms and Sertraline Response in Major Depression Patients

  2008cited by this paper
• Contribution of allelic variations to the phenotype of response to antidepressants and antipsychotics

  2008cited by this paper
• Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patients.

  2008cited by this paper
• Interactive effects of sex and 5-HTTLPR on mood and impulsivity during tryptophan depletion in healthy people.

  2007cited by this paper
• Interaction between SERTPR and stressful life events on response to antidepressant treatment.

  2007cited by this paper
• Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients

  2007influential reference
• Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression.

  2007influential reference
• Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample.

  2007influential reference
• Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study.

  2007influential reference
• Antidepressant response in the elderly.

  2007cited by this paper
• Gender issues in depression.

  2007cited by this paper
• A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment

  2007cited by this paper
• Association study of the serotonin transporter promoter polymorphism and mirtazapine antidepressant response in major depressive disorder.

  2007cited by this paper
• Depression: the benefits of early and appropriate treatment.

  2007cited by this paper
• Dissecting the determinants of depressive disorders outcome: an in depth analysis of two clinical cases

  2007influential reference
• Serotonin transporter polymorphisms and clinical response to sertraline across ethnicities.

  2006cited by this paper
• Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression.

  2006influential reference
• Serotonin transporter gene variants and behavior: a comprehensive review.

  2006influential reference
• Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder

  2006influential reference
• Serotonin transporter polymorphisms and side effects in antidepressant therapy--a pilot study.

  2006influential reference
• Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

  2006cited by this paper
• Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials

  2006cited by this paper
• Effects of the Serotonin Type 2A, 3A and 3B Receptor and the Serotonin Transporter Genes on Paroxetine and Fluvoxamine Efficacy and Adverse Drug Reactions in Depressed Japanese Patients

  2006influential reference
• The combination of duloxetine and bupropion for treatment‐resistant major depressive disorder

  2006cited by this paper
• Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder.

  2006cited by this paper
• Sequence analysis of the serotonin transporter and associations with antidepressant response.

  2005influential reference
• Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review

  2004influential reference
• Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders

  2004cited by this paper
• Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression.

  2004influential reference
• Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

  2004cited by this paper
• Serotonin transporter promoter gene polymorphism and long-term outcome of antidepressant treatment

  2004influential reference
• A meta-analysis of the association between the serotonin transporter gene polymorphism (5-HTTLPR) and trait anxiety

  2004cited by this paper
• The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder

  2004cited by this paper
• Measuring inconsistency in meta-analyses

  2003cited by this paper
• A polymorphism (5-HTTLPR) in the serotonin transporter promoter gene is associated with DSM-IV depression subtypes in seasonal affective disorder

  2003influential reference
• 5-HTTLPR Polymorphism of the Serotonin Transporter Gene Predicts Non-Remission in Major Depression Patients Treated With Citalopram in a 12-Weeks Follow Up Study

  2003cited by this paper
• Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment.

  2003cited by this paper
• The economic burden of depression and the cost‐effectiveness of treatment

  2003cited by this paper
• Tolerability and adherence issues in antidepressant therapy.

  2003cited by this paper
• Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline.

  2003influential reference
• Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome.

  2002influential reference
• Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients.

  2002cited by this paper
• Psychosocial and clinical predictors of response to pharmacotherapy for depression.

  2002cited by this paper
• Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression.

  2001cited by this paper
• Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression.

  2001cited by this paper
• Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene.

  2000cited by this paper
• Serotonin transporter gene polymorphism and antidepressant response

  2000influential reference
• The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants

  2000cited by this paper
• Allelic Variation in the Serotonin Transporter Promoter Affects Onset of Paroxetine Treatment Response in Late-Life Depression

  2000cited by this paper
• Role of serotonin transporter promoter repeat length polymorphism (5-HTTLPR) in seasonality and seasonal affective disorder

  1998cited by this paper
• Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine

  1998influential reference
• Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees.

  1998cited by this paper
• Mode of inheritance in mood disorder families according to fluvoxamine response

  1998cited by this paper
• Serotonin transporter gene polymorphisms: ethnic difference and possible association with bipolar affective disorder

  1997influential reference
• A Sequence variation

  1997cited by this paper
• Meta-analysis: Principles and procedures

  1997cited by this paper
• Allelic Variation of Human Serotonin Transporter Gene Expression

  1996cited by this paper
• THE PROGNOSIS OF ANTIDEPRESSIVE TREATMENTS: LONGITUDINAL AND GENETIC STUDIES.

  1965cited by this paper

• Case Series on Obsessive-compulsive Disorder in Twins: Phenotypic Divergence and Shared Therapeutic Challenges.

  2026cites this paper
• A Cultural Approach to Musical Care: Theoretical Perspectives and Future Directions

  2026cites this paper
• 5-HTTLPR does not moderate the effect of attention bias modification for depression: a randomized sham-controlled trial

  2025cites this paper
• The Role of the 5-HTTLPR Gene Variation of the SLC6A4 Serotonergic System in the Development of Addictive Disorders: A Narrative Review

  2025cites this paper
• Genetics and Neurobiology of Treatment-Resistant Depression—A Review

  2025cites this paper
• Genetic variants of SLC6A4 and risk of coronary artery disease: insights from North Indian population

  2025cites this paper
• Influence of Genetic Variants on Risperidone-Associated Prolactin Elevation in Thai Pediatric ASD Patients

  2025cites this paper
• Integrating multi-polygenic scores for enhanced prediction of antidepressant treatment outcomes in an East Asian population

  2025cites this paper
• Polymorphic variants of SLC6A4 and TPH1 genes as predictors of sertraline efficacy and safety in patients with mixed anxiety-depressive disorder: a pilot study

  2025cites this paper
• TDM as a tool for pharmacogenetic patient profiling: a case report of phenoconversion

  2025cites this paper
• Racial and Ethnic Considerations for the Clinical Practice of Psychopharmacology and Research Methodology: A Narrative Review of the Growing Body of Literature

  2025cites this paper
• Analysis of SLC6A4 (5 ‑HTTLPR) gene polymorphism depending on clinical features and efficacy of therapeutic and rehabilitation measures in patients with psychostimulant addiction

  2024cites this paper
• Challenges and Opportunities in Managing Geriatric Depression: The Role of Personalized Medicine and Age-Appropriate Therapeutic Approaches

  2024cites this paper
• Pharmacogenomic and Pharmacometabolomic Biomarkers of the Efficacy and Safety of Antidepressants: Focus on Selective Serotonin Reuptake Inhibitors

  2024cites this paper
• The Role of Pharmacogenetics in Personalizing the Antidepressant and Anxiolytic Therapy

  2023cites this paper
• The Role of Genetics in the Development and Pharmacotherapy of Depression and Its Impact on Drug Discovery

  2023cites this paper
• Relationships between serotonin availability and frontolimbic response to fearful and threatening faces

  2023cites this paper
• Meta-Analysis of the Association Between 5-Hydroxytryptamine Transporter Gene-Linked Polymorphic Region and Functional Dyspepsia and its Subtypes

  2023cites this paper
• Pharmacogenomics in allogeneic hematopoietic stem cell transplantation: Implications on supportive therapies and conditioning regimens.

  2023cites this paper
• Deciphering the Effect of Different Genetic Variants on Hippocampal Subfield Volumes in the General Population

  2023cites this paper
• Review of pharmacogenomics of psychiatric comorbidities in autism spectrum disorder.

  2023cites this paper
• A Bibliometric and Visual Analysis of Single Nucleotide Polymorphism Studies in Depression

  2023cites this paper
• Organic cation transporters in psychiatric and substance use disorders

  2023cites this paper
• Precision Medicine in Antidepressants Treatment.

  2023cites this paper
• Pharmacogenetics of selective serotonin reuptake inhibitors (SSRI): A serotonin reuptake transporter (SERT)-based approach.

  2023cites this paper
• Ethnopsychopharmacology: Clinical and scientific writing pearls

  2023cites this paper
• Role of serotonin transporter and receptor gene polymorphisms in treatment response to selective serotonin reuptake inhibitors in major depressive disorder

  2022influential citation
• Pharmacogenetic Interventions Improve the Clinical Outcome of Treatment-Resistant Autistic Spectrum Disorder Sufferers

  2022cites this paper
• Study on the Relationship between 5-HttLPR Gene and BDNF Gene Polymorphism and Post-Traumatic Stress Disorder in Li and Han Nationality of Hainan Province

  2022cites this paper
• Region-specific microRNA alterations in marmosets carrying SLC6A4 polymorphisms are associated with anxiety-like behavior

  2022cites this paper
• Association of intron 4 VNTR polymorphism in the NOS3 gene with rapid cycling and treatment resistance in bipolar disorder: a case-control study

  2022cites this paper
• Uncovering Functional Contributions of PMAT (Slc29a4) to Monoamine Clearance Using Pharmacobehavioral Tools

  2022cites this paper
• Genotyping of patients treated with selective serotonin reuptake inhibitors.

  2022cites this paper
• Case report: Non-response to fluoxetine in a homozygous 5-HTTLPR S-allele carrier of the serotonin transporter gene

  2022cites this paper
• FARMAKOGENETİĞİN ANTİDEPRESANLARIN KLİNİK KULLANIMI ÜZERİNE ETKİSİ

  2022cites this paper
• Association of two specific haplotypes of serotonin transporter gene with fluvoxamine treatment outcomein Iranian patients with obsessive compulsive disorder

  2021cites this paper
• Pharmacogenetically Guided Escitalopram Treatment for Pediatric Anxiety Disorders: Protocol for a Double-Blind Randomized Trial

  2021cites this paper
• Psicotrópicos y Farmacogenética

  2021cites this paper
• Effectiveness of Mindfulness-Based Cognitive Therapy for Positive Clinical Outcome in Panic Disorder: a 5-year Longitudinal Study

  2021cites this paper
• A Decade of Pharmacogenetic Studies in Jordan: A Systemic Review

  2021cites this paper
• Lost in translation. The quest for definitions of treatment-resistant depression with a focus on inflammation-related gene expression

  2021cites this paper
• Antidepressant efficacy of oral ketamine treatment

  2021cites this paper
• Biomarkers

  2021cites this paper
• Biomarkers in Child and Adolescent Depression

  2021cites this paper
• Constitutive Serotonin Tone Modulates Molecular and Behavioral Response to Chronic Fluoxetine Treatment: A Study on Genetic Rat Model

  2021cites this paper
• Pediatric psychiatric disorders

  2021cites this paper
• Pharmacogenetic/Pharmacogenomic Tests for Treatment Prediction in Depression.

  2021cites this paper
• Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants

  2021cites this paper
• Pharmacogenomics Factors Influencing the Effect of Risperidone on Prolactin Levels in Thai Pediatric Patients With Autism Spectrum Disorder

  2021cites this paper
• Applying Pharmacogenomics in Drug Therapy of Neurologic and Psychiatric Disorders

  2021cites this paper
• Serotonergic gene-to-gene interaction is associated with mood and GABA concentrations but not with pain-related cerebral processing in fibromyalgia subjects and healthy controls

  2021cites this paper
• A prospective study to determine the clinical utility of pharmacogenetic testing of veterans with treatment-resistant depression

  2021influential citation
• Therapygenetic effects of 5-HTTLPR on cognitive-behavioral therapy in anxiety disorders: A meta-analysis.

  2021cites this paper
• Treatment-Resistant Depression Revisited: A Glimmer of Hope

  2021cites this paper
• Pharmacogenetic‐based management of depression: Role of traditional Persian medicine

  2021cites this paper
• Developmental Antecedents of Adult Macaque Neurogenesis: Early-Life Adversity, 5-HTTLPR Polymorphisms, and Adolescent Hippocampal Volume.

  2021cites this paper
• Challenges and Opportunities in Implementing Pharmacogenetic Testing in Clinical Settings.

  2020cites this paper
• Enrichment Environment Positively Influences Depression- and Anxiety-Like Behavior in Serotonin Transporter Knockout Rats through the Modulation of Neuroplasticity, Spine, and GABAergic Markers

  2020cites this paper
• Neuropsychiatric issues after stroke: Clinical significance and therapeutic implications

  2020cites this paper
• The association between serotonin-related gene polymorphisms and susceptibility and early sertraline response in patients with panic disorder

  2020cites this paper
• Association between genetic polymorphism and antidepressants in major depression: a network meta-analysis.

  2020cites this paper
• Partial Support for an Interaction Between a Polygenic Risk Score for Major Depressive Disorder and Prenatal Maternal Depressive Symptoms on Infant Right Amygdalar Volumes.

  2020cites this paper
• Genetic Markers for Later Remission in Response to Early Improvement of Antidepressants

  2020cites this paper
• Association between serotonin - related gene polymorphisms and e arly effects of  sertraline in Chinese Han patients with panic disorder

  2020cites this paper
• Where and when were the studies conducted? An examination of articles published in 2017-2018 in two leading Indian psychiatry journals.

  2020cites this paper
• Pharmacogenetic association of bi- and triallelic polymorphisms of SLC6A4 with antidepressant response in major depressive disorder.

  2020cites this paper
• Pharmacogenomics: an Update for Child and Adolescent Psychiatry

  2020cites this paper
• Prognosis and Improved Outcomes in Major Depression: A Review.

  2020cites this paper
• Leveraging genetics to enhance the efficacy of PTSD pharmacotherapies.

  2020cites this paper
• 5HTTLPR Genetic Variant and Major Depressive Disorder: A Review

  2020cites this paper
• Antidepressant-like effects of ketamine in a mouse model of serotonergic dysfunction.

  2020cites this paper
• Pharmacogenomics of treatment response in major depressive disorder

  2020cites this paper
• The increasing challenge of the possible impact of ethnicity on psychopharmacology

  2020cites this paper
• Association of Serotonin Transporter Gene (5-HTTLPR/rs25531) Polymorphism with Comorbidities of Panic Disorder

  2020cites this paper
• Clinical validation of combinatorial pharmacogenomic testing and single-gene guidelines in predicting psychotropic medication blood levels and clinical outcomes in patients with depression.

  2020cites this paper
• Depression and inflammation: implications for cardiovascular disease

  2020influential citation
• Serotonin Transporter Gene Promoter Hypomethylation as a Predictor of Antidepressant Treatment Response in Major Depression: A Replication Study

  2020cites this paper
• Pharmacogenomic Studies in Intellectual Disabilities and Autism Spectrum Disorder: A Systematic Review

  2020cites this paper
• Association between functional polymorphisms in serotonin transporter gene (SLC6A4) and escitalopram treatment response in depressive patients in a South Indian population

  2020cites this paper
• A biocultural approach to psychiatric illnesses

  2019cites this paper
• Cytochrome P450 2C19 Poor Metabolizer Phenotype in Treatment Resistant Depression: Treatment and Diagnostic Implications

  2019cites this paper
• Pharmacogenetics of Sertraline Tolerability and Response in Pediatric Anxiety and Depressive Disorders

  2019cites this paper
• Association Study Between Serotonin Transporter Gene and Fluoxetine Response in Mexican Patients With Major Depressive Disorder

  2019cites this paper
• Prognosis and improved outcomes in major depression: a review

  2019cites this paper
• Personalized TMS: role of RNA genotyping

  2019cites this paper
• Major Risk Factors of Depression: A Study in a Specialized Hospital, Dhaka, Bangladesh

  2019cites this paper
• Psychiatric disorders and SLC6A4 gene variants: possible effects on alcohol dependence and alzheimer’s disease

  2019cites this paper
• Genetic variants in major depressive disorder: From pathophysiology to therapy

  2019cites this paper
• Tackling Missing Heritability by Use of an Optimum Curve: A Systematic Review and Meta-Analysis

  2019cites this paper
• Associations of the serotonin transporter promoter polymorphism (5‐HTTLPR) with bipolar disorder and treatment response: A systematic review and meta‐analysis

  2019cites this paper
• Clinical Utilization of Pharmacogenetics in Psychiatry – Perspectives of Pharmacists, Genetic Counselors, Implementation Science, Clinicians, and Industry

  2019cites this paper
• Reconstruction and Analysis of Gene Networks of Human Neurotransmitter Systems Reveal Genes with Contentious Manifestation for Anxiety, Depression, and Intellectual Disabilities

  2019cites this paper
• Efficacy and safety of duloxetine and Pregabalin in Iranian patients with diabetic peripheral neuropathic pain: a double-blind, randomized clinical trial

  2019cites this paper
• Implications of Pharmacogenomics in Depression Pathophysiology and Treatment

  2019cites this paper
• Divergence of an association between depressive symptoms and a dopamine polygenic score in Caucasians and Asians

  2019cites this paper
• Chronic Systemic Symptoms in Head and Neck Cancer Patients.

  2019cites this paper
• Novel susceptibility genes were found in a targeted sequencing of stroke patients with or without depression in the Chinese Han population.

  2019cites this paper
• Pharmacogenetics of Antidepressants: from Genetic Findings to Predictive Strategies

  2019cites this paper
• Pharmacogenomics in Psychiatric Disorders

  2019cites this paper
• Pharmacogenomics and Biomarkers of Depression.

  2019cites this paper